beta

GTH

Genetron Holdings Ltd

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

genetron holdings limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. the company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as hccscreen, a proprietary assay for the early screening of liver cancer. it also provides in-vitro diagnostics products, including 8-gene lung cancer assay, an ivd assay product based on semiconductor sequencing to detect lung cancer; genetron 3d biochip reading instrument; idh1/tert gene assays for glioma; genetron s5, a semiconductor sequencer used in the field of gene detection; and genetron s2000 that enables gene panel sequencing. in addition, the company develops ctdna lung cancer assay for mutations in the epidermal growth factor receptor gene. it also offers development services in the areas of genomics research and clinical development in collabor

Market Cap: 123 Million

Primary Exchange: NASDAQ

Website: genetronhealth.com

Shares Outstanding: 31.6 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.10134602841016799

Sector: Health Care and Social Assistance

Industry: Medical Laboratories

Ethical Flags

Longest drawdown: 996 trading days

From: 2021-02-12 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud